The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
BITT Announces Exclusivity Agreement with MSRD and NIH Funding for TNFR2 Clinical Trial
Aug 16, 2024•almost 2 years ago
Contract Type
agreement
BostonBiotechnologyHealth CareTherapeutics
Description
Boston Immune Technologies and Therapeutics, Inc. (BITT) has announced a sponsored research and exclusivity agreement with the McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies. MSRD will finance key non-human primate studies for the pre-clinical development of BITT’s CD40 antagonist in exchange for an exclusive right to negotiate an acquisition, license or collaboration agreement related to the asset. BITT has also received a $4M National Institute of Health/National Cancer Institute grant to support the ongoing Phase I clinical trial of BITT’s lead TNFR2 antagonist.
Company Information
Company
Boston Immune Technologies and Therapeutics (BITT)
Location
Boston, Massachusetts, United States
About
BITT is a Boston, MA-based company developing a novel class of antagonist antibodies targeting TNF superfamily receptors for applications in oncology, inflammation, autoimmunity, and infectious disease based on the company’s DOMab™ platform.
Predictive Intelligence
Strategic
ML-powered predictions for Boston Immune Technologies and Therapeutics (BITT)'s next move
BostonBiotechnologyHealth CareTherapeutics